Physician profile
Joseph E Johnson
NPI 1477557072
$835.21
in general payments reported to CMS, 2019-2025
9 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.25 · 2020: $81.96 · 2021: $123 · 2022: $62.98 · 2023: $110 · 2024: $191 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $374 · Education: $98.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $374.36 |
| Education | $98.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $328.09 | 2019-2025 | Stelara, Tremfya |
| Abbvie INC. | $223.26 | 2021-2025 | |
| Echosens North America, INC. | $107.89 | 2025 | Fibroscan |
| Merck Sharp & Dohme LLC | $58.56 | 2023 | Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.52 | 2020-2021 | |
| Shionogi INC | $31.34 | 2019 | |
| Medtronic, INC. | $15.32 | 2024 | Gi Genius |
| Nestle Healthcare Nutrition INC. | $15.23 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$28,506.37 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.